Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Four new option listings on August 24th » 08:30
08/24/22
08/24
08:30
08/24/22
08:30
APGN

Apexigen

$4.94 /

-0.15 (-2.95%)

, RXST

RxSight

$13.36 /

-0.14 (-1.04%)

, UGRO

Urban-Gro

$3.77 /

+0.07 (+1.89%)

New option listings for…

New option listings for August 24th include APE Stock (APE), Apexigen Inc (APGN), RxSight Inc (RXST), and Urban Gro Inc (UGRO).

ShowHide Related Items >><<
UGRO Urban-Gro
$3.77 /

+0.07 (+1.89%)

APGN Apexigen
$4.94 /

-0.15 (-2.95%)

APGN Apexigen
$4.94 /

-0.15 (-2.95%)

RXST RxSight
$13.36 /

-0.14 (-1.04%)

04/19/22 BTIG
J&J results will be viewed favorably for MedTech group, says BTIG
04/08/22 Needham
RxSight initiated with a Buy at Needham
08/24/21 SVB Securities
SVB Leerink bullish on RxSight, initiates with an Outperform
UGRO Urban-Gro
$3.77 /

+0.07 (+1.89%)

08/16/22 Maxim
Urban-Gro price target lowered to $12 from $20 at Maxim
05/02/22 Craig-Hallum
Craig-Hallum bullish on Urban-Gro, initiates with a Buy
05/02/22 Craig-Hallum
Urban-Gro initiated with a Buy at Craig-Hallum
03/21/22 Maxim
Urban-Gro initiated with a Buy at Maxim
UGRO Urban-Gro
$3.77 /

+0.07 (+1.89%)

RXST RxSight
$13.36 /

-0.14 (-1.04%)

UGRO Urban-Gro
$3.77 /

+0.07 (+1.89%)

Syndicate
RxSight files $200M mixed securities shelf  16:37
08/08/22
08/08
16:37
08/08/22
16:37
RXST

RxSight

$15.64 /

+0.21 (+1.36%)

 
ShowHide Related Items >><<
RXST RxSight
$15.64 /

+0.21 (+1.36%)

04/19/22 BTIG
J&J results will be viewed favorably for MedTech group, says BTIG
04/08/22 Needham
RxSight initiated with a Buy at Needham
08/24/21 SVB Securities
SVB Leerink bullish on RxSight, initiates with an Outperform
08/24/21 JPMorgan
RxSight initiated with an Overweight at JPMorgan
RXST RxSight
$15.64 /

+0.21 (+1.36%)

Earnings
RxSight raises FY22 revenue view to $44M-$46M from $41.5M-$45.5M » 16:23
08/08/22
08/08
16:23
08/08/22
16:23
RXST

RxSight

$15.64 /

+0.21 (+1.36%)

FY22 revenue consensus…

FY22 revenue consensus $43.97M. The revised guidance range implies an annual growth rate versus 2021 of 95% to 104%. The company has increased its 2022 gross margin guidance range to 37% to 38% of revenue, up from the previous range of 35% to 36% of revenue. The Company also narrowed its operating expense guidance to a range of $88.0 million to $90.0 million compared to prior guidance of $86.0 million to $90.0 million.

ShowHide Related Items >><<
RXST RxSight
$15.64 /

+0.21 (+1.36%)

04/19/22 BTIG
J&J results will be viewed favorably for MedTech group, says BTIG
04/08/22 Needham
RxSight initiated with a Buy at Needham
08/24/21 SVB Securities
SVB Leerink bullish on RxSight, initiates with an Outperform
08/24/21 JPMorgan
RxSight initiated with an Overweight at JPMorgan
RXST RxSight
$15.64 /

+0.21 (+1.36%)

Earnings
RxSight reports Q2 EPS adjusted EPS (50c) vs ($3.24) last year » 16:22
08/08/22
08/08
16:22
08/08/22
16:22
RXST

RxSight

$15.64 /

+0.21 (+1.36%)

Reports Q2 revenue…

Reports Q2 revenue $11.36M, consensus $10.75M. "In the second quarter of 2022, RxSight continued to establish a track record of strong year-over-year and sequential growth, driven by vigorous demand for our LDD and accelerating utilization of our LAL," said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. "Our progress thus far reflects the powerful benefits doctors and patients derive when they choose our unique LAL system, enabling them to achieve excellent vision without glasses or compromises."

ShowHide Related Items >><<
RXST RxSight
$15.64 /

+0.21 (+1.36%)

04/19/22 BTIG
J&J results will be viewed favorably for MedTech group, says BTIG
04/08/22 Needham
RxSight initiated with a Buy at Needham
08/24/21 SVB Securities
SVB Leerink bullish on RxSight, initiates with an Outperform
08/24/21 JPMorgan
RxSight initiated with an Overweight at JPMorgan
RXST RxSight
$15.64 /

+0.21 (+1.36%)

Syndicate
RxSight announces $50M 'at-the-market' equity offering program » 16:14
08/08/22
08/08
16:14
08/08/22
16:14
RXST

RxSight

$15.64 /

+0.21 (+1.36%)

RxSight announced that it…

RxSight announced that it has filed a $200M shelf registration statement with the SEC. Once declared effective by the SEC, the shelf registration statement would permit the company to sell, from time to time, up to $200M in aggregate value of its common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement is intended to provide the company with flexibility to access additional capital when market conditions are appropriate. As part of the shelf registration, the company also filed a prospectus supplement to sell, of the $200M of securities being registered, up to an aggregate of $50M of its common stock through an "at-the-market" offering. The shares will be offered through BofA Securities as sales agent. The registration statement has been filed with the SEC, but has not yet become effective.

ShowHide Related Items >><<
RXST RxSight
$15.64 /

+0.21 (+1.36%)

04/19/22 BTIG
J&J results will be viewed favorably for MedTech group, says BTIG
04/08/22 Needham
RxSight initiated with a Buy at Needham
08/24/21 SVB Securities
SVB Leerink bullish on RxSight, initiates with an Outperform
08/24/21 JPMorgan
RxSight initiated with an Overweight at JPMorgan
RXST RxSight
$15.64 /

+0.21 (+1.36%)

Over a quarter ago
Earnings
RxSight sees 2022 revenue $41.5M-$45.5M vs. prior $40M-$44M » 16:33
05/05/22
05/05
16:33
05/05/22
16:33
RXST

RxSight

$10.57 /

-1.01 (-8.72%)

Consensus $42.26M. The…

Consensus $42.26M. The company did not change its guidance for 2022 gross margin or operating expenses, which are ranges of 35% to 36% of revenue, and $86M to $90M, respectively.

ShowHide Related Items >><<
RXST RxSight
$10.57 /

-1.01 (-8.72%)

04/19/22 BTIG
J&J results will be viewed favorably for MedTech group, says BTIG
04/08/22 Needham
RxSight initiated with a Buy at Needham
08/24/21 SVB Securities
SVB Leerink bullish on RxSight, initiates with an Outperform
08/24/21 JPMorgan
RxSight initiated with an Overweight at JPMorgan
RXST RxSight
$10.57 /

-1.01 (-8.72%)

  • 30
    Jul
Earnings
RxSight reports Q1 EPS (64c), consensus (65c) » 16:32
05/05/22
05/05
16:32
05/05/22
16:32
RXST

RxSight

$10.57 /

-1.01 (-8.72%)

Reports Q1 revenue $8.9M,…

Reports Q1 revenue $8.9M, consensus $7.32M. The company said, "We are very pleased with our strong start to 2022. Solid revenue growth, driven by an expanding installed base and rising procedure volumes, confirms that an increasing number of doctors and patients are selecting our premium cataract solution for the significant advantages it provides. We are confident in our ability to execute our growth strategy in 2022 and beyond by continuing to focus on our core strengths: exceptional visual outcomes across a range of patient types and preferences, a positive and interactive patient experience that achieves high satisfaction and a convincing value proposition for premium cataract practices and their patients."

ShowHide Related Items >><<
RXST RxSight
$10.57 /

-1.01 (-8.72%)

04/19/22 BTIG
J&J results will be viewed favorably for MedTech group, says BTIG
04/08/22 Needham
RxSight initiated with a Buy at Needham
08/24/21 SVB Securities
SVB Leerink bullish on RxSight, initiates with an Outperform
08/24/21 JPMorgan
RxSight initiated with an Overweight at JPMorgan
RXST RxSight
$10.57 /

-1.01 (-8.72%)

  • 30
    Jul
Recommendations
J&J results will be viewed favorably for MedTech group, says BTIG » 11:12
04/19/22
04/19
11:12
04/19/22
11:12
JNJ

Johnson & Johnson

$182.93 /

+5.29 (+2.98%)

, ALC

Alcon

$78.26 /

+1.92 (+2.52%)

, GKOS

Glaukos

$61.36 /

+2.09 (+3.53%)

, GMED

Globus Medical

$76.85 /

+0.52 (+0.68%)

, ISRG

Intuitive Surgical

$291.60 /

+15.89 (+5.76%)

, LNSR

Lensar

$7.60 /

+0.16 (+2.15%)

, NUVA

NuVasive

$59.82 /

+3.485 (+6.19%)

, RXST

RxSight

$13.12 /

+0.455 (+3.59%)

, STAA

Staar Surgical

$64.45 /

+2.95 (+4.80%)

, SPNE

SeaSpine

$10.76 /

+0.44 (+4.26%)

, SYK

Stryker

$271.45 /

+12.665 (+4.89%)

Johnson &…

Johnson & Johnson's (JNJ) Q1 sales in its MedTech business were better than consensus expectations and "encouraging" against a tough comp from FY21, even when accounting for an extra selling day this year that benefited results by 190 basis points, said BTIG analyst Ryan Zimmerman. The analyst, who thinks J&J's MedTech results will be viewed favorably as procedural recovery continues into Q2, also notes the company's commentary on margin pressures, raw material increases, and foreign exchanges being headwinds through the remainder of FY22. Zimmerman's MedTech coverage includes Alcon (ALC), Glaukos (GKOS), Globus Medical (GMED), Intuitive Surgical (ISRG), Lensar (LNSR), NuVasive (NUVA), RxSight (RXST), Staar Surgical (STAA), SeaSpine (SPNE) and Stryker (SYK).

ShowHide Related Items >><<
SYK Stryker
$271.45 /

+12.665 (+4.89%)

STAA Staar Surgical
$64.45 /

+2.95 (+4.80%)

SPNE SeaSpine
$10.76 /

+0.44 (+4.26%)

NUVA NuVasive
$59.82 /

+3.485 (+6.19%)

LNSR Lensar
$7.60 /

+0.16 (+2.15%)

JNJ Johnson & Johnson
$182.93 /

+5.29 (+2.98%)

ISRG Intuitive Surgical
$291.60 /

+15.89 (+5.76%)

GMED Globus Medical
$76.85 /

+0.52 (+0.68%)

GKOS Glaukos
$61.36 /

+2.09 (+3.53%)

ALC Alcon
$78.26 /

+1.92 (+2.52%)

JNJ Johnson & Johnson
$182.93 /

+5.29 (+2.98%)

04/14/22 Raymond James
Johnson & Johnson price target raised to $195 from $185 at Raymond James
04/06/22 Morgan Stanley
Johnson & Johnson assumed with an Equal Weight at Morgan Stanley
03/16/22 Bernstein
Bernstein downgrades J&J on 'uphill battle' for Janssen unit
03/16/22 Bernstein
Johnson & Johnson downgraded to Market Perform from Outperform at Bernstein
ALC Alcon
$78.26 /

+1.92 (+2.52%)

04/08/22 Needham
Alcon initiated with a Buy at Needham
03/11/22 BofA
Alcon initiated with a Buy at BofA
02/17/22 JPMorgan
Alcon price target lowered to CHF 69 from CHF 72.20 at JPMorgan
01/18/22 Stephens
Alcon downgraded to Equal Weight from Overweight at Stephens
GKOS Glaukos
$61.36 /

+2.09 (+3.53%)

04/18/22 BTIG
Glaukos price target raised to $66 from $61 at BTIG
03/02/22 Stifel
Glaukos transferred with Hold rating at Stifel
02/23/22 Citi
Glaukos price target raised to $55 from $49 at Citi
02/03/22 William Blair
Glaukos upgraded to Outperform from Market Perform at William Blair
GMED Globus Medical
$76.85 /

+0.52 (+0.68%)

04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
04/12/22 Truist
Globus Medical assumed with a Buy at Truist
03/28/22 Wells Fargo
Globus Medical initiated with an Overweight at Wells Fargo
03/28/22 Wells Fargo
Globus Medical initiated with an Overweight at Wells Fargo
ISRG Intuitive Surgical
$291.60 /

+15.89 (+5.76%)

04/13/22 Deutsche Bank
Intuitive Surgical antitrust case heading to trial, says Deutsche Bank
04/12/22 Truist
Intuitive Surgical initiated with a Buy at Truist
04/05/22 Wolfe Research
Intuitive Surgical initiated with a Peer Perform at Wolfe Research
LNSR Lensar
$7.60 /

+0.16 (+2.15%)

11/22/21 BTIG
Lensar initiated with a Buy at BTIG
NUVA NuVasive
$59.82 /

+3.485 (+6.19%)

04/12/22 Truist
NuVasive assumed with a Buy at Truist
03/28/22 Wells Fargo
Wells Fargo bullish on NuVasive, initiates with an Overweight
03/28/22 Wells Fargo
NuVasive initiated with an Overweight at Wells Fargo
RXST RxSight
$13.12 /

+0.455 (+3.59%)

04/08/22 Needham
RxSight initiated with a Buy at Needham
08/24/21 SVB Securities
SVB Leerink bullish on RxSight, initiates with an Outperform
08/24/21 JPMorgan
RxSight initiated with an Overweight at JPMorgan
08/24/21 BofA
RxSIGHT initiated with Buy at BofA on differentiated technology
STAA Staar Surgical
$64.45 /

+2.95 (+4.80%)

04/08/22 Needham
Staar Surgical initiated with a Buy at Needham
03/28/22 Benchmark
Staar Surgical upgraded to Buy from Hold at Benchmark
03/18/22 BTIG
Staar Surgical upgraded to Buy at BTIG on improving fundamentals in second half
03/18/22 BTIG
Staar Surgical upgraded to Buy from Neutral at BTIG
SPNE SeaSpine
$10.76 /

+0.44 (+4.26%)

04/12/22 Truist
SeaSpine assumed with a Buy at Truist
03/14/22 Piper Sandler
SeaSpine price target lowered to $21 from $28 at Piper Sandler
12/21/21 Truist
SeaSpine price target lowered to $20 from $25 at Truist
SYK Stryker
$271.45 /

+12.665 (+4.89%)

04/18/22 BTIG
Stryker price target raised to $278 from $273 at BTIG
04/12/22 Truist
Stryker initiated with a Hold at Truist
04/11/22 RBC Capital
Stryker receipt of outpatient facility code a 'positive,' says RBC Capital
SYK Stryker
$271.45 /

+12.665 (+4.89%)

STAA Staar Surgical
$64.45 /

+2.95 (+4.80%)

SPNE SeaSpine
$10.76 /

+0.44 (+4.26%)

RXST RxSight
$13.12 /

+0.455 (+3.59%)

NUVA NuVasive
$59.82 /

+3.485 (+6.19%)

LNSR Lensar
$7.60 /

+0.16 (+2.15%)

JNJ Johnson & Johnson
$182.93 /

+5.29 (+2.98%)

ISRG Intuitive Surgical
$291.60 /

+15.89 (+5.76%)

GMED Globus Medical
$76.85 /

+0.52 (+0.68%)

GKOS Glaukos
$61.36 /

+2.09 (+3.53%)

ALC Alcon
$78.26 /

+1.92 (+2.52%)

  • 30
    Jul
SYK Stryker
$271.45 /

+12.665 (+4.89%)

JNJ Johnson & Johnson
$182.93 /

+5.29 (+2.98%)

ISRG Intuitive Surgical
$291.60 /

+15.89 (+5.76%)

GMED Globus Medical
$76.85 /

+0.52 (+0.68%)

SYK Stryker
$271.45 /

+12.665 (+4.89%)

STAA Staar Surgical
$64.45 /

+2.95 (+4.80%)

SPNE SeaSpine
$10.76 /

+0.44 (+4.26%)

JNJ Johnson & Johnson
$182.93 /

+5.29 (+2.98%)

ISRG Intuitive Surgical
$291.60 /

+15.89 (+5.76%)

GMED Globus Medical
$76.85 /

+0.52 (+0.68%)

GKOS Glaukos
$61.36 /

+2.09 (+3.53%)

ALC Alcon
$78.26 /

+1.92 (+2.52%)

SYK Stryker
$271.45 /

+12.665 (+4.89%)

JNJ Johnson & Johnson
$182.93 /

+5.29 (+2.98%)

ISRG Intuitive Surgical
$291.60 /

+15.89 (+5.76%)

GKOS Glaukos
$61.36 /

+2.09 (+3.53%)

Initiation
RxSight initiated with a Buy at Needham » 05:42
04/08/22
04/08
05:42
04/08/22
05:42
RXST

RxSight

$13.48 /

-0.1 (-0.74%)

Needham analyst David…

Needham analyst David Saxon initiated coverage of RxSight with a Buy rating and $18 price target. The RxSight System is a "differentiated" intraocular lens that can result in better visual outcomes for the patient, Saxon tells investors in a research note. The analyst believes this could drive adoption despite the incremental capital equipment required. His doctor checks suggest RxSight's intraocular lens could be appropriate for up to 20% of the cataract patient population. Saxon finds the shares attractively valued at current levels.

ShowHide Related Items >><<
RXST RxSight
$13.48 /

-0.1 (-0.74%)

08/24/21 SVB Securities
SVB Leerink bullish on RxSight, initiates with an Outperform
08/24/21 JPMorgan
RxSight initiated with an Overweight at JPMorgan
08/24/21 BofA
RxSIGHT initiated with Buy at BofA on differentiated technology
08/24/21 SVB Securities
RxSIGHT initiated with an Outperform at SVB Leerink
RXST RxSight
$13.48 /

-0.1 (-0.74%)

  • 30
    Jul
Earnings
RxSight sees FY22 revenue $40M-$44M, consensus $38.47M » 16:23
03/08/22
03/08
16:23
03/08/22
16:23
RXST

RxSight

$12.13 /

-1.14 (-8.59%)

The company said,…

The company said, "RxSight projects 2022 full year revenue to be between $40.0 million and $44.0 million, full year gross margin of 35% to 36% of revenue and full year operating expenses of $86.0 million to $90.0 million."

ShowHide Related Items >><<
RXST RxSight
$12.13 /

-1.14 (-8.59%)

08/24/21 SVB Securities
SVB Leerink bullish on RxSight, initiates with an Outperform
08/24/21 JPMorgan
RxSight initiated with an Overweight at JPMorgan
08/24/21 BofA
RxSIGHT initiated with Buy at BofA on differentiated technology
08/24/21 SVB Securities
RxSIGHT initiated with an Outperform at SVB Leerink
RXST RxSight
$12.13 /

-1.14 (-8.59%)

  • 30
    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.